Automate Your Wheel Strategy on CVS
With Tiblio's Option Bot, you can configure your own wheel strategy including CVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CVS
- Rev/Share 310.5469
- Book/Share 57.6123
- PB 1.3369
- Debt/Equity 1.121
- CurrentRatio 0.8319
- ROIC 0.0043
- MktCap 97530497823.0
- FreeCF/Share 4.959
- PFCF 15.4983
- PE 207.8833
- Debt/Assets 0.3202
- DivYield 0.0346
- ROE 0.0062
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CVS | Goldman | -- | Buy | -- | $91 | Oct. 14, 2025 |
| Upgrade | CVS | UBS | Neutral | Buy | -- | $79 | Aug. 18, 2025 |
| Upgrade | CVS | Robert W. Baird | Neutral | Outperform | -- | $82 | Aug. 14, 2025 |
| Upgrade | CVS | Leerink Partners | Market Perform | Outperform | $55 | $75 | Feb. 13, 2025 |
| Upgrade | CVS | Cantor Fitzgerald | Neutral | Overweight | -- | -- | Feb. 12, 2025 |
| Upgrade | CVS | Edward Jones | Hold | Buy | -- | -- | Jan. 30, 2025 |
| Upgrade | CVS | Deutsche Bank | Hold | Buy | -- | $66 | Dec. 3, 2024 |
| Upgrade | CVS | Barclays | Equal Weight | Overweight | $63 | $82 | Oct. 10, 2024 |
| Upgrade | CVS | TD Cowen | Hold | Buy | $59 | $85 | Oct. 4, 2024 |
News
CVS bids for Rite Aid stores, Bloomberg News reports
Published: May 15, 2025 by: Reuters
Sentiment: Positive
Healthcare conglomerate CVS Health has bid for a significant number of stores and patient data from bankrupt pharmacy chain operator Rite Aid, Bloomberg News reported on Thursday.
Read More
UNH Stock Vs. CVS Stock
Published: May 15, 2025 by: Forbes
Sentiment: Negative
Health insurance companies have been in the limelight lately after UnitedHealthcare suspended its guidance for the full year citing higher medical costs. This comes during a challenging time when the CEO Andrew Witty also stepped down for ‘personal reasons.
Read More
5 Low Price-to-Book Value Stocks to Buy in May
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks.
Read More
4 Value Picks to Ride the Market Rebound After US-China Trade Thaw
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. STNE, CNC, CVS & PFE boast a low P/CF ratio.
Read More
CVS Health celebrates reopening of Hendersonville store destroyed by Hurricane Helene
Published: May 12, 2025 by: PRNewsWire
Sentiment: Neutral
The South Main Street CVS Pharmacy is again providing health, wellness and pharmacy services to customers and patients WOONSOCKET, R.I. , May 12, 2025 /PRNewswire/ -- Today, leaders from CVS Health® (NYSE: CVS) were joined by state and local representatives to celebrate the reopening of one of its Hendersonville CVS Pharmacy stores.
Read More
Levi & Korsinsky Investigates Possible Securities Fraud Violations by CVS Health Corporation (CVS)
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CVS Health Corporation ("CVS Health Corporation") (NYSE:CVS) concerning possible violations of federal securities laws. The U.S. Department of Justice filed a complaint on May 1, 2025, against insurance broker organizations, including CVS, alleging that "insurers paid hundreds of millions of dollars in illegal kickbacks to the defendant brokers in exchange for enrollments in the insurers' Medicare Advantage plans.
Read More
CVS Health: Big 2025 Momentum, Strong Growth Ahead, Shares Underpriced
Published: May 11, 2025 by: Seeking Alpha
Sentiment: Positive
CVS Health has shown impressive year-to-date performance, driven by strong Q1 results and strategic shifts in its business model. I reiterate a buy rating on CVS due to its low valuation, mixed technicals, and promising earnings growth prospects. Key catalysts include improved performance in Healthcare Benefits, higher star ratings in Medicare Advantage, and strategic exits from less profitable areas.
Read More
CVS vs. DHR: Which Stock Is the Better Value Option?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical Services sector might want to consider either CVS Health (CVS) or Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
ATTENTION CVS SHAREHOLDERS: Investors Who Lost Money on CVS Health Corporation Are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CVS Health Corporation ("CVS Health Corporation") (NYSE:CVS) concerning possible violations of federal securities laws. The U.S. Department of Justice filed a complaint on May 1, 2025, against insurance broker organizations, including CVS, alleging that "insurers paid hundreds of millions of dollars in illegal kickbacks to the defendant brokers in exchange for enrollments in the insurers' Medicare Advantage plans.
Read More
GLP-1 competition heats up: Novo Nordisk CEO talks Wegovy, CVS deal, earnings
Published: May 07, 2025 by: Yahoo Finance
Sentiment: Positive
Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94).
Read More
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Published: May 07, 2025 by: CNBC
Sentiment: Neutral
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Read More
Kirby McInerney LLP Announces Investigation of Claims Against CVS Health Corporation (CVS) on Behalf of Investors
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against CVS Health Corporation (“CVS” or the “Company”) (NYSE:CVS). The investigation concerns whether CVS and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
Read More
Build A 12%+ Yield On Cost By 2035 With May's Top 10 High-Yield Picks
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
In this article, I present 10 attractive high-yield investment options for this month of May 2025, which not only offer dividend income but also potential for dividend growth. The selection process involves analyzing financial ratios, competitive advantages, valuations, and diversification across industries and countries to minimize risks and maximize returns. Highlighted top picks for May 2025 include VICI Properties, Chevron, Canadian Natural Resources, Pfizer, Altria, CVS Health, Toronto-Dominion Bank, Comcast, Vale, and Ares Capital.
Read More
What Makes CVS Health (CVS) a New Buy Stock
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
CVS Health (CVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Wall Street Analysts Think CVS Health (CVS) Is a Good Investment: Is It?
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now?
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
CVS Health (CVS) is a Top-Ranked Value Stock: Should You Buy?
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment
Published: May 01, 2025 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S NVO announced that CVS Health Inc's CVS CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy (semaglutide) injection 2.4 mg will soon be the preferred GLP-1 medicine on its largest commercial template formularies.
Read More
CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Negative
Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly's obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to CVS's exclusion, creating a temporary mispricing in Lilly's stock, presenting a potential buying opportunity. Despite CVS's exclusion, Zepbound still has broad market access through other PBMs and regional health plans, ensuring continued sales growth.
Read More
CVS earnings: Things are finally clicking for the healthcare giant
Published: May 01, 2025 by: Yahoo Finance
Sentiment: Positive
CVS (CVS) stock jumped after beating first quarter earnings and revenue expectations. Jefferies Healthcare Services equity research analyst Brian Tanquilut explains how CVS's margin recovery and business diversification signal growing investor confidence.
Read More
Initial Claims More Than Expectations
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Initial Claims More Than Expectations.
Read More
CVS Health: Why I'm Not Buying The Post-Earnings Share Buoyancy
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
CVS Health Corporation's Q1 2025 earnings show strong growth, with revenues up 7% YoY and adjusted EPS up 72%, but caution is advised for the long-term outlook. Despite positive quarterly results, CVS downgraded its full-year 2025 revenue guidance and faces ongoing challenges in its Medicare Advantage business. CVS is addressing issues in its Health Care Benefits division by terminating unprofitable contracts and improving star ratings, but risks remain high.
Read More
CVS Health (CVS) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
CVS Health Corporation (NYSE:CVS ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants David Joyner - President, Chief Executive Officer Tom Cowhey - Executive Vice President, Chief Financial Officer Prem Shah - Group President, CVS Health Steve Nelson - President, Aetna Larry McGrath - Chief Strategy Officer, Investor Relations Conference Call Participants Justin Lake - Wolfe Research Lisa Gill - JP Morgan Stephen Baxter - Wells Fargo Elizabeth Anderson - Evercore ISI Andrew Mok - Barclays Michael Cherny - Leerink Partners Charles Rhyee - TD Cowen Ann Hynes - Mizuho Securities Operator Good morning and …
Read More
CVS Health raises full-year profit outlook as Q1 earnings top estimates
Published: May 01, 2025 by: Proactive Investors
Sentiment: Positive
CVS Health Corp (NYSE:CVS) shares rose after the pharmacy chain raised its full-year profit guidance and delivered strong financial results for the first quarter. The company now expects 2025 adjusted earnings per share (EPS) in the range of $6 to $6.20, up from its earlier guidance of $5.75 to $6.
Read More
Compared to Estimates, CVS Health (CVS) Q1 Earnings: A Look at Key Metrics
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for CVS Health (CVS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
QCOM Earnings Sell-Off, CVS Turnaround Continues, LLY Disappoints
Published: May 01, 2025 by: Schwab Network
Sentiment: Neutral
While Microsoft (MSFT) and Meta Platforms (META) shined in the Big Tech space, Diane King Hall turns to a mixed earnings picture elsewhere on Wall Street. CVS Health (CVS) posted an earnings beat, raised guidance, and announced a Wegovy deal with Novo Nordisk (NVO), all contributing to its rally.
Read More
CVS Q1 Earnings & Revenues Beat, '25 EPS View Raised, Stock Up
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
CVS Health delivers earnings and revenue beat in the first quarter of 2025.
Read More
CVS Health Stock Surges as Q1 Results Handily Top Estimates
Published: May 01, 2025 by: Investopedia
Sentiment: Positive
CVS Health (CVS) shares powered 9% higher before the bell Thursday after the pharmacy and healthcare giant's first-quarter results handily topped estimates.
Read More
CVS Health (CVS) Q1 Earnings and Revenues Beat Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
CVS Health (CVS) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.31 per share a year ago.
Read More
CVS Health's stock surges toward a one-year high after an earnings triple play
Published: May 01, 2025 by: Market Watch
Sentiment: Positive
Shares of CVS Health Corp. CVS jumped 6.6% toward a one-year high in premarket trading Thursday, after the healthcare-services company and drugstore chain scored a triple-play with its earnings report, by beating and profit and revenue and raising its full-year outlook.
Read More
About CVS Health Corporation (CVS)
- IPO Date 1996-11-20
- Website https://www.cvshealth.com
- Industry Medical - Healthcare Plans
- CEO J. David Joyner
- Employees 219000